Dazukibart for dermatomyositis: expanding the therapeutic arsenal

Iago Pinal-Fernandez^{1

2}, Maria Casal-Dominguez^{1

2}, Andrew L Mammen^{1

2}

Affiliations

¹ Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
² Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

PMID: 40689076
PMCID: PMC12272793
DOI: 10.21037/atm-25-44

Editorial

Dazukibart for dermatomyositis: expanding the therapeutic arsenal

Iago Pinal-Fernandez et al. Ann Transl Med. 2025.

. 2025 Jun 27;13(3):24.

doi: 10.21037/atm-25-44. Epub 2025 Jun 24.

Authors

Iago Pinal-Fernandez^{1

2}, Maria Casal-Dominguez^{1

2}, Andrew L Mammen^{1

2}

Affiliations

¹ Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
² Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

PMID: 40689076
PMCID: PMC12272793
DOI: 10.21037/atm-25-44

No abstract available

Keywords: Dermatomyositis; dazukibart; interferon; myositis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-25-44/coif). The authors have no conflicts of interest to declare.

Comment on

Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Fiorentino D, Mangold AR, Werth VP, Christopher-Stine L, Femia A, Chu M, Musiek ACM, Sluzevich JC, Graham LV, Fernandez AP, Aggarwal R, Rieger K, Page KM, Li X, Hyde C, Rath N, Sloan A, Oemar B, Banerjee A, Salganik M, Banfield C, Neelakantan S, Beebe JS, Vincent MS, Peeva E, Vleugels RA. Fiorentino D, et al. Lancet. 2025 Jan 11;405(10473):137-146. doi: 10.1016/S0140-6736(24)02071-3. Lancet. 2025. PMID: 39798982 Clinical Trial.

References

1. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-78. 10.1002/ana.20464 - DOI - PubMed
1. Huard C, Gullà SV, Bennett DV, et al. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis. Br J Dermatol 2017;176:1224-30. 10.1111/bjd.15006 - DOI - PubMed
1. Liao AP, Salajegheh M, Nazareno R, et al. Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis 2011;70:831-6. 10.1136/ard.2010.139949 - DOI - PubMed
1. Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, et al. Identification of distinctive interferon gene signatures in different types of myositis. Neurology 2019;93:e1193-204. 10.1212/WNL.0000000000008128 - DOI - PMC - PubMed
1. Pinal-Fernandez I, Muñoz-Braceras S, Casal-Dominguez M, et al. Pathological autoantibody internalisation in myositis. Ann Rheum Dis 2024;83:1549-60. 10.1136/ard-2024-225773 - DOI - PMC - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- AME Publishing Company
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Dazukibart for dermatomyositis: expanding the therapeutic arsenal

Affiliations

Dazukibart for dermatomyositis: expanding the therapeutic arsenal

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

References

Publication types

LinkOut - more resources

Full Text Sources